<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666832</url>
  </required_header>
  <id_info>
    <org_study_id>2017-10-150</org_study_id>
    <nct_id>NCT03666832</nct_id>
  </id_info>
  <brief_title>Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel</brief_title>
  <acronym>MP-PDAC-01</acronym>
  <official_title>Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joon Oh Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Inclusion&#xD;
&#xD;
             1. Subjects who are males or females ≥ 19 years of age&#xD;
&#xD;
             2. Subjects who have the following history of first-line gemcitabine and&#xD;
                nab-paclitaxel among patients with cytologically or histologically proven&#xD;
                metastatic pancreatic ductal adenocarcinoma&#xD;
&#xD;
             3. Subjects who can give written informed consent for participation in this trial&#xD;
                after receiving explanations of this trial&#xD;
&#xD;
             4. Subjects who have the following laboratory test values:&#xD;
&#xD;
                  -  bilirubin ≤ 1.5 x ULN (upper limit of normal)&#xD;
&#xD;
                  -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN&#xD;
&#xD;
                  -  serum creatinine ≤ 1.5 x ULNor estimated creatinine clearance ≥ 40 mL/min&#xD;
                     (Cockcroft-Gault)&#xD;
&#xD;
                  -  partial thromboplastin time (aPTT) ≤ 1.5 x ULN&#xD;
&#xD;
                  -  absolute neutrophil count (ANC) ≥ 1,500 cells/µL&#xD;
&#xD;
                  -  platelet count ≥ 100,000/µL&#xD;
&#xD;
                  -  hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
             5. Subjects who have at least a 12-week life expectancy at the Investigator's&#xD;
                discretion&#xD;
&#xD;
             6. Subjects who have Eastern Cooperative Oncology Group (ECOG)Performance Status 0-1&#xD;
&#xD;
        -  Exclusion&#xD;
&#xD;
             1. Subjects who were treated with surgery, radiotherapy, chemotherapy or&#xD;
                investigational therapy within 2 weeks (note: placement of biliary stent is&#xD;
                allowed)&#xD;
&#xD;
             2. Subjects who have uncontrolled CNS metastases (patients who require steroids should&#xD;
                be on a stable or decreasing dose for at least 2 weeks)&#xD;
&#xD;
             3. Subjects who have any contraindications for 5-FU, leucovorin, or oxaliplatin&#xD;
&#xD;
             4. Subjects who have moderate or severe cardiovascular disease&#xD;
&#xD;
                  -  Subjects who have myocardial infarction, unstable angina pectoris, New York&#xD;
                     Heart Association (NYHA) Class III/IV congestive heart failure, or&#xD;
                     uncontrolled hypertension within 6 months before screening&#xD;
&#xD;
                  -  Subjects who have major abnormalities at the Investigator's discretion based&#xD;
                     on electrocardiogram (ECG)and Doppler ECHO results at screening or within 14&#xD;
                     days before screening&#xD;
&#xD;
                  -  Subjects who have increase in brain natriuretic peptide(BNP) or increase in&#xD;
                     troponin (over 99th percentile upper reference limit) at Screening (based on&#xD;
                     the normal range of relevant study center)&#xD;
&#xD;
                  -  Subjects who have risk factors for ascending aortic aneurysm such as genetic&#xD;
                     disorder and trauma and risk factors for aortic stenosis&#xD;
&#xD;
                  -  Subjects who have a history of heart or aorta surgery&#xD;
&#xD;
             5. Subjects who have clinically significant gastrointestinal bleeding within 4 weeks&#xD;
                before screening&#xD;
&#xD;
             6. Subjects who have a known history or suspected hypersensitivity to any excipients&#xD;
                of the investigational product or combination drug(s)&#xD;
&#xD;
             7. Subjects who have received prior treatment targeting the signaling pathway of TGF-β&#xD;
&#xD;
             8. Subjects who have a disease or condition that affects the mechanism of the&#xD;
                investigational product, or are currently using or planning to use:&#xD;
&#xD;
                  -  Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme&#xD;
                     (CYP) including CYP1A2, CYP2B6, or CYP3A4&#xD;
&#xD;
                  -  Drugs that are exclusively or primarily eliminated by UDP&#xD;
                     glucuronyltransferase (UGT) 1A1 (UGT1A1)&#xD;
&#xD;
                  -  Drugs that are substrates for the drug transporter multidrug resistance&#xD;
                     protein 1 (MDR1) have a narrow therapeutic window or are strong inhibitors of&#xD;
                     drug transporter MDR1&#xD;
&#xD;
                  -  Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4&#xD;
&#xD;
             9. Subjects who are unable to swallow tablets&#xD;
&#xD;
            10. Subjects who have a history of or are suspected of drug abuse&#xD;
&#xD;
            11. Female subjects of child-bearing potential who have a positive result on a&#xD;
                pregnancy test at screening or are unable to agree to use an effective barrier&#xD;
                method of birth control to avoid pregnancy during the study period (e.g.,&#xD;
                sterilization, intrauterine contraceptive device, combination of oral contraception&#xD;
                and barrier contraception, combination of other hormone delivery systems and&#xD;
                barrier contraception, contraceptive cream, combination of cream, jelly, or form&#xD;
                and diaphragm or condom)&#xD;
&#xD;
            12. Subjects, in the opinion of the Investigator, who are unsuitable to participate in&#xD;
                the study&#xD;
&#xD;
            13. Subjects who were treated with other investigational products within 28 days before&#xD;
                screening or within a period shorter than 5-timesthe half-life of the&#xD;
                investigational product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregression free survival</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEW-7197</intervention_name>
    <description>TEW-7197 1cycle 14days&#xD;
-intake 5days, rest 2days</description>
    <arm_group_label>Arm1</arm_group_label>
    <other_name>TEW-7197, FOLFOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Subjects who are males or females ≥ 19 years of age 2) Subjects who have the&#xD;
             following history of first-line gemcitabine and nab-paclitaxel among patients with&#xD;
             cytologically or histologically proven metastatic pancreatic ductal adenocarcinoma 3)&#xD;
             Subjects who can give written informed consent for participation in this trial after&#xD;
             receiving explanations of this trial 4) Subjects who have the following laboratory&#xD;
             test values:&#xD;
&#xD;
          -  bilirubin ≤ 1.5 x ULN (upper limit of normal)&#xD;
&#xD;
          -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN&#xD;
&#xD;
          -  serum creatinine ≤ 1.5 x ULNor estimated creatinine clearance ≥ 40 mL/min&#xD;
             (Cockcroft-Gault)&#xD;
&#xD;
          -  partial thromboplastin time (aPTT) ≤ 1.5 x ULN&#xD;
&#xD;
          -  absolute neutrophil count (ANC) ≥ 1,500 cells/µL&#xD;
&#xD;
          -  platelet count ≥ 100,000/µL&#xD;
&#xD;
          -  hemoglobin ≥ 9.0 g/dL 5) Subjects who have at least a 12-week life expectancy at the&#xD;
             Investigator's discretion 6) Subjects who have Eastern Cooperative Oncology Group&#xD;
             (ECOG)Performance Status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Subjects who were treated with surgery, radiotherapy, chemotherapy or&#xD;
             investigational therapy within 2 weeks (note: placement of biliary stent is allowed)&#xD;
             2) Subjects who have uncontrolled CNS metastases (patients who require steroids should&#xD;
             be on a stable or decreasing dose for at least 2 weeks) 3) Subjects who have any&#xD;
             contraindications for 5-FU, leucovorin, or oxaliplatin 4) Subjects who have moderate&#xD;
             or severe cardiovascular disease&#xD;
&#xD;
          -  Subjects who have myocardial infarction, unstable angina pectoris, New York Heart&#xD;
             Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension&#xD;
             within 6 months before screening&#xD;
&#xD;
          -  Subjects who have major abnormalities at the Investigator's discretion based on&#xD;
             electrocardiogram (ECG)and Doppler ECHO results at screening or within 14 days before&#xD;
             screening&#xD;
&#xD;
          -  Subjects who have increase in brain natriuretic peptide(BNP) or increase in troponin&#xD;
             (over 99th percentile upper reference limit) at Screening (based on the normal range&#xD;
             of relevant study center)&#xD;
&#xD;
          -  Subjects who have risk factors for ascending aortic aneurysm such as genetic disorder&#xD;
             and trauma and risk factors for aortic stenosis&#xD;
&#xD;
          -  Subjects who have a history of heart or aorta surgery 5) Subjects who have clinically&#xD;
             significant gastrointestinal bleeding within 4 weeks before screening 6) Subjects who&#xD;
             have a known history or suspected hypersensitivity to any excipients of the&#xD;
             investigational product or combination drug(s) 7) Subjects who have received prior&#xD;
             treatment targeting the signaling pathway of TGF-β 8) Subjects who have a disease or&#xD;
             condition that affects the mechanism of the investigational product, or are currently&#xD;
             using or planning to use:&#xD;
&#xD;
          -  Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme (CYP)&#xD;
             including CYP1A2, CYP2B6, or CYP3A4&#xD;
&#xD;
          -  Drugs that are exclusively or primarily eliminated by UDP glucuronyltransferase (UGT)&#xD;
             1A1 (UGT1A1)&#xD;
&#xD;
          -  Drugs that are substrates for the drug transporter multidrug resistance protein 1&#xD;
             (MDR1) have a narrow therapeutic window or are strong inhibitors of drug transporter&#xD;
             MDR1&#xD;
&#xD;
          -  Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4 9) Subjects who are&#xD;
             unable to swallow tablets 10) Subjects who have a history of or are suspected of drug&#xD;
             abuse 11) Female subjects of child-bearing potential who have a positive result on a&#xD;
             pregnancy test at screening or are unable to agree to use an effective barrier method&#xD;
             of birth control to avoid pregnancy during the study period (e.g., sterilization,&#xD;
             intrauterine contraceptive device, combination of oral contraception and barrier&#xD;
             contraception, combination of other hormone delivery systems and barrier&#xD;
             contraception, contraceptive cream, combination of cream, jelly, or form and diaphragm&#xD;
             or condom) 12) Subjects, in the opinion of the Investigator, who are unsuitable to&#xD;
             participate in the study 13) Subjects who were treated with other investigational&#xD;
             products within 28 days before screening or within a period shorter than 5-timesthe&#xD;
             half-life of the investigational product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>joonoh park, Ph MD</last_name>
    <phone>82-2-2148-7394</phone>
    <email>oncopark66@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Oh Park, M.D., Ph.D</last_name>
      <phone>82 2 3410 3459</phone>
      <email>oncopark@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>yoon Jeong Ahn</last_name>
      <phone>221487395</phone>
      <phone_ext>82</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Oh Park</investigator_full_name>
    <investigator_title>Samsung Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

